BioCentury
ARTICLE | Financial News

Athenex ticks up after $66M IPO

June 14, 2017 11:29 PM UTC

Cancer company Athenex Inc. (NASDAQ:ATNX) gained $1.56 (14%) to $12.56 in its first day of trading Thursday after it raised $66 million through the sale of 6 million shares at $11 in an IPO underwritten by Credit Suisse, Deutsche Bank, JPMorgan, and ICBC International Securities. The IPO price valued Athenex at $607.7 million.

The company said earlier this month that it hoped to sell 6 million shares at $11-$13. At the $12 midpoint, a sale of that many shares would have raised $72 million and valued the company at $663 million...

BCIQ Company Profiles

Athenex Inc.

Eli Lilly and Co.

BCIQ Target Profiles

P glycoprotein